Aktienanalyse wird geladen …
HSIC · NASDAQ · Medical Distribution · USA
85,02 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 13,18 Mrd. | 398 Mio. | 3,27 $ | 121,72 Mio. | 0,5 Mio · 0,4 % | 6,5 Mio · 5,4 % | 31,1 % | 3 % | 4,71 $ | 0,32 $ | — |
| 2024 | 12,67 Mrd. | 390 Mio. | 3,05 $ | 127,78 Mio. | 0,5 Mio · 0,4 % | 4,4 Mio · 3,5 % | 31,7 % | 3,1 % | 5,48 $ | 0,31 $ | — |
| 2023 | 12,34 Mrd. | 416 Mio. | 3,16 $ | 131,75 Mio. | 0,5 Mio · 0,3 % | 6,5 Mio · 4,9 % | 31,3 % | 3,4 % | 2,68 $ | 0,30 $ | — |
| 2022 | 12,65 Mrd. | 538 Mio. | 3,91 $ | 137,76 Mio. | 0,6 Mio · 0,5 % | 4,7 Mio · 3,4 % | 30,3 % | 4,3 % | 3,67 $ | 0,39 $ | — |
| 2021 | 12,4 Mrd. | 631 Mio. | 4,45 $ | 141,77 Mio. | 0,9 Mio · 0,6 % | 2,5 Mio · 1,8 % | 29,6 % | 5,1 % | 4,45 $ | 0,55 $ | — |
| 2020 | 10,12 Mrd. | 404 Mio. | 2,82 $ | 143,4 Mio. | 0,1 Mio · 0,1 % | 6 Mio · 4,2 % | 27,8 % | 4 % | 3,84 $ | 0,06 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 3,46 Mrd. | 94 Mio. | 0,82 $ | 114,39 Mio. | 31,8 % | 2,7 % | 1,85 $ |
| Q1 2026 | 3,37 Mrd. | 107 Mio. | 0,92 $ | 116,06 Mio. | 31,8 % | 3,2 % | -1,05 $ |
| Q4 2025 | 3,44 Mrd. | 101 Mio. | 0,83 $ | — | 30,9 % | 2,9 % | 2,78 $ |
| Q3 2025 | 3,34 Mrd. | 101 Mio. | 0,83 $ | 121,04 Mio. | 30,7 % | 3 % | 1,16 $ |
| Q2 2025 | 3,24 Mrd. | 86 Mio. | 0,70 $ | 122,64 Mio. | 31,4 % | 2,7 % | 0,72 $ |
| Q1 2025 | 3,17 Mrd. | 110 Mio. | 0,88 $ | 124,85 Mio. | 31,6 % | 3,5 % | 0,05 $ |
| Q4 2024 | 3,19 Mrd. | 94 Mio. | 0,77 $ | — | 31,1 % | 3 % | 1,38 $ |
| Q3 2024 | 3,17 Mrd. | 99 Mio. | 0,78 $ | 127,05 Mio. | 31,3 % | 3,1 % | 0,92 $ |
Are Investors Undervaluing Henry Schein (HSIC) Right Now?
What Makes Henry Schein (HSIC) a New Buy Stock
HSIC or SAUHY: Which Is the Better Value Stock Right Now?
DermaSensor Raises $5 Million and Opens Round to the Public via Wefunder, Alongside Four Major New US Partnerships
Henry Schein to Distribute Applied BioCode's MDx-3000 System in US
Henry Schein to Participate in Upcoming Investor Conference in September
Henry Schein (HSIC) is an Incredible Growth Stock: 3 Reasons Why
Why Is Henry Schein (HSIC) Up 0.9% Since Last Earnings Report?
Henry Schein, Inc. is a health care solutions company that serves office-based dental, medical, and veterinary professionals. Henry Schein provides a broad range of products and services through its core businesses in healthcare distribution, specialty products, and technology-enabled value-added services. Its offerings include consumable supplies, dental equipment, practice-management software, logistics support, and related clinical solutions that help practices manage daily operations more efficiently. The company also supports dental laboratories, government and institutional health care clinics, and other alternate care sites with products and services tailored to professional workflows. With a strong presence in dental and medical markets, Henry Schein plays an important role in the supply chain for outpatient health care providers and practice support services.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest HSIC und jede andere Aktie unbegrenzt.